This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Shire Pharmaceuticals Group PLC
Drug Names(s): Natpar [EU], NPSP558, ALX1-11, Preos, parathyroid hormone 1-84 [rDNA origin] injection, PTH 1-84
Description: BioMedTracker has separate drug profiles for PTH-184. Please also see Preotact, as it is known in Europe. The revenue model for osteoporosis can be seen in the Preotact profile.
A recombinant human parathyroid hormone, which differs from currently available antiresorptive treatments because it is anabolic. That means it has the potential to reverse bone loss rather than just reduce bone resorption.
NPS and Nycomed
Nycomed will be responsible for European clinical development, registration and marketing of PREOS. Nycomed has agreed to make an equity investment in NPS of $40 million by purchasing common shares subject to customary closing conditions, pay NPS up to $25 million in milestones upon regulatory approvals and achievement of certain sales targets, and pay NPS royalties on sales in Europe. Nycomed will also be responsible for conducting Phase IIIb and IV clinical trials in Europe, representing a minimum additional investment of $25 million.
Takeda and Nycomed
In May 2011, Takeda Pharmaceutical and Nycomed A/S jointly announced that Takeda has reached an agreement with the shareholders of Nycomed in which Takeda will acquire the company for 9.6 billion Euro on a cash-free, debt-free basis. The purchase would exclude Nycomed's U.S. dermatology business. The acquisition closed in September 2011.
NPS and Takeda
In March 2013, NPS...See full deal structure in Biomedtracker
Partners: DRI Capital Inc.
Additional information available to subscribers only: